Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells

J Endocrinol. 2002 Aug;174(2):233-46. doi: 10.1677/joe.0.1740233.

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) acts as a glucose-dependent growth factor for beta-cells. Here we show that GIP and glucose also act synergistically as anti-apoptotic factors for beta-cells, using the well-differentiated beta-cell line, INS-1. Mitogenic and anti-apoptotic signaling of GIP were dependent upon pleiotropic activation of protein kinase A (PKA)/cAMP regulatory element binder (CREB), mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3-kinase)/PKB signaling modules. The signaling modules activated by GIP were dependent on glucose metabolism and calcium influx and were tightly linked by multiple activating and inhibiting cross-talk. These interactions included: (i) a central role of tyrosine phosphorylation for stimulation of PKA/CREB, MAPK and PI3-kinase/PKB, (ii) inhibition of PKA/CREB by the MAPK pathway at the level of MAPK kinase-1 or downstream, (iii) activation of MAPK signaling by PI3-kinase and PKA at the level of extracellular-signal regulated kinase 1/2 or upstream, and (iv) activation of PKB by MAPK and PKA signaling at the level of PKB or upstream. Furthermore, we demonstrated inhibition of CREB signaling by Ca(2+)/calmodulin kinase I/IV. These results indicated that GIP acts as a mitogenic and anti-apoptotic factor for beta-cells by pleiotropic activation of tightly linked signaling pathways in beta-cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives*
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
  • Alloxan / pharmacology
  • Androstadienes / pharmacology
  • Apoptosis / drug effects
  • Arginase / genetics
  • B-Lymphocytes / metabolism*
  • Benzylamines / pharmacology
  • Calcium / metabolism
  • Calcium-Calmodulin-Dependent Protein Kinases / antagonists & inhibitors
  • Cell Line
  • Chelating Agents / pharmacology
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Deoxyglucose / pharmacology
  • Egtazic Acid / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology
  • Gastric Inhibitory Polypeptide / pharmacology*
  • Genistein / pharmacology
  • Glucokinase / antagonists & inhibitors
  • Glucose / metabolism
  • Humans
  • Indoles / pharmacology
  • Isoquinolines / pharmacology
  • MAP Kinase Kinase 1
  • MAP Kinase Signaling System / drug effects
  • Maleimides / pharmacology
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Mitosis / drug effects*
  • Phosphoinositide-3 Kinase Inhibitors
  • Plasmids
  • Protein Kinase C / antagonists & inhibitors
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Signal Transduction / drug effects*
  • Sulfonamides / pharmacology
  • Wortmannin

Substances

  • Androstadienes
  • Benzylamines
  • Chelating Agents
  • Enzyme Inhibitors
  • Flavonoids
  • Indoles
  • Isoquinolines
  • Maleimides
  • Phosphoinositide-3 Kinase Inhibitors
  • Sulfonamides
  • KN 93
  • Egtazic Acid
  • Gastric Inhibitory Polypeptide
  • KN 62
  • Alloxan
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • Deoxyglucose
  • Genistein
  • Glucokinase
  • Protein-Tyrosine Kinases
  • Protein Serine-Threonine Kinases
  • Cyclic AMP-Dependent Protein Kinases
  • Protein Kinase C
  • Calcium-Calmodulin-Dependent Protein Kinases
  • MAP Kinase Kinase 1
  • MAP2K1 protein, human
  • Mitogen-Activated Protein Kinase Kinases
  • Arginase
  • Glucose
  • bisindolylmaleimide I
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Calcium
  • Wortmannin